期刊文献+

Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis 被引量:2

Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis
下载PDF
导出
摘要 Patients with severe alcoholic hepatitis (AH) need to be treated with specific treatment for better outcome.Currently available specific treatment modalities are use of corticosteroids or pentoxifylline.However,the response rate to these drugs is only about 50%-60%.Hence,there is an urgent need for better and more effective treatment options.Tumor necrosis factor plays an important role in the pathogenesis of AH.However,agents blocking the action of tumor necrosis factor have not been found to be effective.Rather the randomized studies evaluating these agents showed an adverse effect and more infections in treated patients.Critical role of tumor necrosis factor in hepatic regen-eration explaining this contrast is discussed.Oxidative stress and inflammation derived from gut bacteria ate two main components in the pathogenesis of AH laying foundation for the role of antioxidants,probiotics,and antibiotics in the management of AH.This article reviews the current data and status of these newer agents for the treatment of AH.Of the various options available,Vitamin E and N-acetylcysteine (NAC) have shown great promise for clinical use as adjunct to corticosteroids.With these encouraging data,future well designed studies are suggested to assess Vitamin E and NAC before their routine use in clinical practice in the management of AH. Patients with severe alcoholic hepatitis (AH) need to be treated with specific treatment for better outcome. Currently available specific treatment modalities are use of corticosteroids or pentoxifylline. However, the response rate to these drugs is only about 50%-60%. Hence, there is an urgent need for better and more effective treatment options. Tumor necrosis factor plays an important role in the pathogenesis of AH. However, agents blocking the action of tumor necrosis factor have not been found to be effective. Rather the randomized studies evaluating these agents showed an adverse effect and more infections in treated patients. Critical role of tumor necrosis factor in hepatic regeneration explaining this contrast is discussed. Oxidative stress and inflammation derived from gut bacteria ate two main components in the pathogenesis of AH laying foundation for the role of antioxidants, probiotics, and antibiotics in the management of AH. This article reviews the current data and status of these newer agents for the treatment of AH. Of the various options available, Vitamin E and N-acetylcysteine (NAC) have shown great promise for clinical use as adjunct to corticosteroids. With these encouraging data, future well designed studies are suggested to assess Vitamin E and NAC before their routine use in clinical practice in the management of AH.
出处 《World Journal of Hepatology》 CAS 2011年第8期211-214,共4页 世界肝病学杂志(英文版)(电子版)
关键词 ALCOHOLIC hepatitis Tumor necrosis factor-α inhibitors INFLIXIMAB ETANERCEPT Antioxidants PROBIOTICS RIFAXIMIN BETAINE Granulocytapheresis Alcoholic hepatitis Tumor necrosis factor-α inhibitors Infliximab Etanercept Antioxidants Probiotics Rifaximin Betaine Granulocytapheresis
  • 相关文献

参考文献25

  • 1Karim Samara MD,Chen Liu,Consuelo Soldevila-Pico,David R. Nelson MD,Manal F. Abdelmalek MD, MPH.Betaine Resolves Severe Alcohol-Induced Hepatitis and Steatosis Following Liver Transplantation[J]. Digestive Diseases and Sciences . 2006 (7)
  • 2Ngyen-Khac E,Thevenot T,Piquet MA,Benferhat S,Hezam A,Goria O,Chatelain D,Tramier B,Dewaele F,Grhib S,Rudler M,Carbonell N,Tossou H,Bental A,Bernard-Chaber B,Dupas JL.Treatment of severe acute alcoholic hepa- titis (AAH) with cortioids plus N-acetylcysteine (C+NAC) versus corticoids alone (C):a multicenter randomized con- trolled trial [Abstract]. Hepatology . 2009
  • 3Vlachogiannakos J,Saveriadis AS,Viazis N,Theodoropou- los I,Foudoulis K,Manolakopoulos S,Raptis S,Karamanolis DG.Intestinal decontamination improves liver haemo-dynamics in patients with alcohol-related decompensated cirrhosis. Alimentary Pharmacology and Therapeutics . 2009
  • 4Morris JM,Dickson S,Neilson M,Hodgins P,Forrest EH.Granulocytapheresis in the treatment of severe alcoholic hepatitis:a case series. European Journal of Gastroenterology and Hepatology . 2010
  • 5Maher JJ.Cytokines:overview. Seminars in Liver Disease . 1999
  • 6Sharma P,Kumar A,Sharma B C,et al.Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival:An open label trial. Journal of Hepatology . 2009
  • 7Naveau S,Chollet-Martin S,Dharancy S, et al.A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology . 2004
  • 8Boetticher NC,Peine CJ,Kwo P,Abrams GA,Patel T,Aqel B,Boardman L,Gores GJ,Harmsen WS,McClain CJ,Kamath PS,Shah VH.A randomized,double-blinded,placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology . 2008
  • 9Stewart S,Prince M,Bassendine M,Hudson M,James O,Jones D,Record C,Day CP.A randomized trial of antioxi- dant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology . 2007
  • 10Mezey E,Potter JJ,Rennie-Tankersley L,Caballeria J,Pares A.A randomized placebo controlled trial of vitamin E for alco-holic hepatitis. Journal of Hepatology . 2004

共引文献9

同被引文献5

引证文献2

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部